Physician profile
Derek R Smith
NPI 1407869019
$468,988.28
in general payments reported to CMS, 2019-2025
64 companies · $77K in 2025
The $77K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138K · 2020: $59K · 2021: $37K · 2022: $62K · 2023: $43K · 2024: $53K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Consulting Fee: $30K · Food and Beverage: $24K · Travel and Lodging: $7,359 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,025.00 |
| Consulting Fee | $30,106.00 |
| Food and Beverage | $24,439.38 |
| Travel and Lodging | $7,359.18 |
| Education | $151.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $147,861.29 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $83,052.58 | 2019-2025 | Evobrutinib, Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $80,252.70 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $40,657.74 | 2020-2025 | Zeposia, Cobenfy |
| Genentech USA, INC. | $31,718.61 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $24,163.70 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $23,400.92 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $11,846.37 | 2021-2023 | Ponvory |
| Genzyme Corporation | $5,796.83 | 2019-2025 | |
| Abbvie INC. | $3,238.59 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Genentech, INC. | $2,893.89 | 2019-2025 | Ocrevus, Enspryng |
| Pfizer INC. | $1,354.45 | 2021-2025 | |
| Amgen INC. | $1,179.95 | 2019-2025 | Uplizna |
| Sunovion Pharmaceuticals INC. | $1,053.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $774.01 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $720.34 | 2022-2025 | Rystiggo, Zilbrysq, Briviact |
| Allergan, INC. | $714.65 | 2019-2022 | |
| Horizon Therapeutics Plc | $569.65 | 2021-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $534.00 | 2023-2025 | Nuedexta, Rexulti |
| Lundbeck LLC | $515.76 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $509.68 | 2020-2024 | Ongentys, Lyvispah |
| Argenx US, INC. | $467.62 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Mallinckrodt Hospital Products INC. | $380.27 | 2020-2025 | Acthar |
| Sumitomo Pharma America, INC. | $375.52 | 2023 | Aptiom |
| Eisai INC. | $368.30 | 2023-2025 | |
| Axsome Therapeutics, INC. | $352.57 | 2023-2025 | Symbravo, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $352.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $343.78 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $330.24 | 2025 | Ponvory, Fanapt |
| Avanir Pharmaceuticals, INC. | $298.04 | 2019-2022 | |
| Abbott Laboratories | $263.03 | 2025 | Infinity |
| Neurocrine Biosciences, INC. | $247.35 | 2024-2025 | Ingrezza |
| Ani Pharmaceuticals, INC. | $239.15 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $219.83 | 2019-2025 | Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $199.15 | 2019-2025 | Ultomiris, Soliris |
| Cycle Pharmaceuticals INC | $180.54 | 2024-2025 | Tascenso Odt, Bafiertam |
| Csl Behring | $171.56 | 2019-2025 | Hizentra |
| Ipsen Biopharmaceuticals, INC | $139.68 | 2023 | Dysport |
| Sk Life Science, INC. | $127.47 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $124.99 | 2023 | Amvuttra |
| Alkermes, INC. | $124.18 | 2025 | Lybalvi |
| Currax Pharmaceuticals LLC | $89.47 | 2020-2024 | Onzetra Xsail |
| Mallinckrodt Enterprises LLC | $88.70 | 2019 | |
| Grifols USA, LLC | $78.78 | 2019-2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $57.85 | 2020-2024 | Hyqvia |
| Supernus Pharmaceuticals, INC. | $50.77 | 2019-2020 | |
| Octapharma USA, INC. | $50.15 | 2024-2025 | Panzyga |
| Upsher-Smith Laboratories LLC | $45.22 | 2022-2023 | |
| Life Molecular Imaging LTD | $40.34 | 2024-2025 | Neuraceq |
| Jazz Pharmaceuticals INC. | $38.95 | 2019-2024 | |
| Tanabe Pharma America, INC. | $37.76 | 2025 | Radicava |
| Scilex Pharmaceuticals INC. | $35.52 | 2023-2024 | Ztlido |
| Almatica Pharma LLC | $33.98 | 2021 | |
| Ge Healthcare | $29.89 | 2025 | |
| Assertio Therapeutics, INC. | $29.33 | 2019 | |
| Convatec INC. | $27.09 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.47 | 2025 | Wainua |
| Averitas Pharma INC. | $23.60 | 2025 | Qutenza |
| Banner Life Sciences, LLC | $21.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.22 | 2020 | |
| Acorda Therapeutics, INC | $18.39 | 2020 | |
| Kyowa Kirin, INC. | $15.78 | 2024 | Nourianz |
| Neurelis, INC. | $15.05 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.